2023-505626-34-01RecruitingPhase 4
PROMISE
PROMISE: Potassium correction for RAAS Optimization in Chronic Kidney Disease
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Dec 2025
Brief summary (registry, in English)
To demonstrate that patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with CKD stage 3b/4, resulting in a significant reduction in albuminuria.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 26 Oct 2023
- Start date
- 16 May 2024
- Lead sponsor
- University Medical Center Groningen
- Diseases
- Chronic kidney disease
- EU CT number
- 2023-505626-34-01
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 44
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease stage 3b-4 who take an ACE inhibitor or ARB blood pressure medicine at less than the highest dose.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Chronic kidney disease stage 3b-4 (eGFR 15-44 mL/min/1.73 m2), with an albumin-creatinine ratio above 3 mg/mmol.
- Earlier treatment
- Must be taking an ACEi/ARB at a sub-maximal dose. Must not have had an ACEi/ARB dose cut in the last year because eGFR fell by more than 25%.
- Biomarker or test result
- Serum potassium (K+) 4.0-5.0 mmol/L. Systolic blood pressure above 130 mmHg, or taking one or more blood pressure drugs.
Main reasons for not taking part
- ACEi/ARB dose cut in the last year because eGFR fell by more than 25%
- Severe high potassium (above 6.0 mmol/L) in the last year
- Pregnancy or breastfeeding
- Life expectancy under 12 months
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Lab values
- Prior ACEi/ARB dose reduction due to a drop in eGFR by >25% in the last year; history of severe hyperkalaemia (>6.0 mmol/L) in the last year; pregnancy or breastfeeding; life expectancy <12 months
Who the study is looking for
- Age ≥ 18 years; CKD stage 3b-4 (eGFR 15-44 mL/min/1.73 m2 - Albumin-creatinine ratio >3 mg/mmol - Systolic blood pressure >130 mmHg or use of one or more antihypertensive drugs; Serum K+ 4.0-5.0 mmol/L; On sub-maximal dose ACEi/ARB
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC | Amsterdam | Netherlands | Recruiting |
| Universitair Medisch Centrum Groningen | Groningen | Netherlands | Recruiting |
| Medisch Centrum Leeuwarden B.V. | Leeuwarden | Netherlands | Recruiting |
| Isala Klinieken Stichting | Zwolle | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.